ALXO trades 1367.2% below Wall Street's consensus target of $17.90.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ALXO achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, ALX Oncology Holdings Inc. (ALXO) has a Wall Street consensus price target of $17.90, based on estimates from 7 covering analysts. With the stock currently trading at $1.22, this represents a potential upside of +1367.2%. The company has a market capitalization of $164M.
Analyst price targets range from a low of $1.50 to a high of $38.00, representing a 204% spread in expectations. The median target of $21.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ALXO trades at a trailing P/E of -0.6x. Analysts expect EPS to grow +6.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 FATEFate Therapeutics, Inc. | $270M | $2.32 | $5.63 | +142.7% | Buy | — | 31 |
 IMVTImmunovant, Inc. | $6.9B | $33.62 | $40.00 | +19.0% | Buy | — | 23 |
 RCUSArcus Biosciences, Inc. | $3.1B | $24.44 | $40.00 | +63.7% | Buy | — | 18 |
 AGENAgenus Inc. | $348M | $8.36 | $25.00 | +199.0% | Buy | 31.3x | 11 |
 NKTRNektar Therapeutics | $1.4B | $43.58 | $146.00 | +235.0% | Buy | — | 33 |
 MGNXMacroGenics, Inc. | $228M | $3.58 | $6.00 | +67.6% | Buy | — | 22 |
 EXELExelixis, Inc. | $14.7B | $58.39 | $51.78 | -11.3% | Hold | 16.6x | 33 |
 HALOHalozyme Therapeutics, Inc. | $13.0B | $109.86 | $103.00 | -6.2% | Buy | 13.1x | 27 |
 TGTXTG Therapeutics, Inc. | $8.3B | $54.29 | $80.50 | +48.3% | Buy | 55.8x | 13 |
 KYMRKymera Therapeutics, Inc. | $8.8B | $107.39 | $138.07 | +28.6% | Buy | — | 27 |
Quick answers to the most common questions about buying ALXO stock.
The consensus Wall Street price target for ALXO is $17.9, representing 1367.2% upside from the current price of $1.22. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ALXO has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $17.9 implies 1367.2% upside from current levels.
ALXO's current price is $1.22 with a consensus target of $17.9 (1367.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $38 for ALXO, while the most conservative target is $1.5. The consensus of $17.9 represents the median expectation. These targets typically reflect 12-month expectations.
ALXO is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ALXO stock forecast based on 7 Wall Street analysts shows a consensus price target of $17.9, with estimates ranging from $1.5 (bear case) to $38 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ALXO, with a "Buy" consensus rating and $17.9 price target (1367.2% upside). 6 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ALXO analyst price targets range from $1.5 to $38, a 204% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $17.9 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.